Ginsenoside Rh2

Ginsenoside Rh2 at a Glance

Ginsenoside Rh2 is a minor protopanaxadiol (PPD)-type saponin of Asian ginseng (Panax ginseng). Structurally it is a monoglucoside — a dammarane triterpene carrying a single sugar at C-3 — which makes it far less polar than the abundant “major” ginsenosides like Rb1. It barely exists in the raw root; what raises it to measurable levels is processing and metabolism: steaming (red and black ginseng), fermentation, and the stepwise stripping of sugars from the big PPD saponins, whether by gut bacteria or in the factory ^{23Reference 23Bae EA et al. · 2004AnimalProtective effect of fermented red ginseng on transient focal ischemic rats (fermentation yields compound K > Rg3 ≥ Rh2) — in vivoView study →24Reference 24Song H et al. · 2020Simultaneous quantification of six nonpolar ginsenosides in white ginseng by reversed-phase HPLC — analyticalView study →}.

Despite its scarcity in nature, Rh2 is one of the most studied minor ginsenosides in cancer research — a deep preclinical literature reports apoptosis, cell-cycle arrest, autophagy modulation, anti-metastatic effects, and sensitization of tumour cells to chemotherapy ^{1Reference 1Hu QR et al. · 2023In vitroThe ways for ginsenoside Rh2 to fight against cancer: the molecular evidences in vitro and in vivo — reviewView study →2Reference 2Guan W · 2023ReviewGinsenoside Rh2: A shining and potential natural product in the treatment of human nonmalignant and malignant diseases in the near future — reviewView study →}. That literature drives a large supplement-marketing industry around “Rh2” products. The honest headline, carried throughout: all of the anticancer evidence is preclinical — cells and rodents — with no randomized human oncology trial of the isolated molecule, and Rh2’s oral bioavailability is poor, which undercuts a straight read-across from a culture dish to a capsule ^{18Reference 18Yang Z et al. · 2011In vitroEnhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms — in vitro/in vivoView study →19Reference 19Wang Z et al. · 2021Pharmacokinetics of ginsenoside Rh2, the major anticancer ingredient of ginsenoside H dripping pills, in healthy subjects — human pharmacokinetic studyView study →}.

A Red-Ginseng Processing Product

Rh2 is best understood not as something the ginseng plant makes in quantity, but as a downstream product of deglycosylation. The root is dominated by large, highly-glycosylated PPD saponins (Rb1, Rc, Rd). Heat and acid during steaming — the step that turns white ginseng into red (and, with repeated steaming, black) ginseng — cleave sugars from these majors, generating a family of less-polar minor ginsenosides: Rg3, Rk1, Rg5, and Rh2 among them ^{24Reference 24Song H et al. · 2020Simultaneous quantification of six nonpolar ginsenosides in white ginseng by reversed-phase HPLC — analyticalView study →}. The same conversion happens biologically: intestinal bacteria (and deliberate fermentation) progressively deglycosylate the majors, and fermented red ginseng has been shown to accumulate compound K > Rg3 ≥ Rh2 as its main saponin metabolites ^{23Reference 23Bae EA et al. · 2004AnimalProtective effect of fermented red ginseng on transient focal ischemic rats (fermentation yields compound K > Rg3 ≥ Rh2) — in vivoView study →}.

Two consequences follow. First, red/steamed/fermented ginseng carries more Rh2 than white ginseng — the reason processed preparations are often marketed as richer in the “active” minor saponins. Second, Rh2 sits one deglycosylation step away from its aglycone, protopanaxadiol (PPD): gut bacteria and gut-wall enzymes convert Rh2 → PPD, so oral Rh2 exposure is partly exposure to PPD ^{21Reference 21Xie HT et al. · 2005In vitroUptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco-2 cells — in vitroView study →22Reference 22Gu Y et al. · 2009AnimalPharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs — in vivoView study →}. This places Rh2 in the same PPD lineage as compound K and Rg3 — related, sugar-stripped molecules that share much of its biology.

20(S) vs. 20(R)-Rh2

Rh2 exists as two epimers that differ only in the orientation of the hydroxyl group at carbon-20: 20(S) and 20(R). This single stereochemical difference is not cosmetic — it governs potency, and nearly all of the anticancer literature uses the 20(S) epimer, which is treated as the biologically active form ^{8Reference 8Bian S et al. · 2021In vitroBian S, et al. (2021). 20(S)-Ginsenoside Rh2-induced apoptosis and protective autophagy in cervical cancer cells by inhibiting the AMPK/mTOR pathway — in vitro. Bioscience, Biotechnology, and Biochemistry. https://pubmed.ncbi.nlm.nih.gov/34718401/View study →13Reference 13Liu ZH et al. · 2015In vitroGinsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells — in vitroView study →14Reference 14Shi Q et al. · 2016In vitroAnticancer effect of 20(S)-ginsenoside Rh2 on HepG2 liver carcinoma cells: activating GSK-3β and degrading β-catenin — in vitroView study →}.

The C-20 configuration changes how the molecule interacts with its targets and with the transporters that move it. In a pharmacokinetic study, 20(S)-Rh2 was the stronger, dose-dependent inhibitor of P-glycoprotein (P-gp), while 20(R)-Rh2 produced weaker, paradoxical effects — and each epimer’s net behaviour in the body depends on the balance between it and its same-configuration PPD metabolite ^{16Reference 16Zhang J et al. · 2012In vitroStereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics — in vitro/in vivoView study →}. Semisynthetic structure–activity work confirms that the C-20 (and C-24) configuration and the number of C-3 sugars are load-bearing for cytotoxicity — potency is a property of the specific stereochemistry, not the “Rh2” name alone ^{17Reference 17Yang J et al. · 2016In vitroSemisynthesis and bioactive evaluation of oxidized products from 20(S)-ginsenoside Rg3, Rh2, protopanaxadiol (PPD) and their 20(R)-epimers as cytotoxic agents — in vitroView study →}.

The practical upshot for reading any Rh2 claim: check which epimer was used. A “20(S)-Rh2” result does not automatically transfer to a “20(R)” preparation, and a commercial “Rh2” ingredient’s activity depends on its epimeric purity — a detail marketing rarely specifies.

Ginsenoside Rh2 in Cancer Research

This is the section the molecule is known for, and the reason to read it critically. Rh2 has been tested against a wide spread of tumour types in vitro and in rodent xenografts, with a recurring set of mechanisms. It is a large, coherent preclinical body ^{1Reference 1Hu QR et al. · 2023In vitroThe ways for ginsenoside Rh2 to fight against cancer: the molecular evidences in vitro and in vivo — reviewView study →2Reference 2Guan W · 2023ReviewGinsenoside Rh2: A shining and potential natural product in the treatment of human nonmalignant and malignant diseases in the near future — reviewView study →} — and it is entirely preclinical: there is no randomized controlled trial of isolated Rh2 as a cancer treatment in people, a gap the supplement market routinely glosses over.

Apoptosis and cell-cycle arrest are the core signals. Across prostate, breast, liver, colon, cervical, oesophageal and leukaemia cell lines, 20(S)-Rh2 induces programmed cell death (caspase activation, a shifted Bax/Bcl-2 balance) and stalls the cell cycle, typically at G1/S ^{3Reference 3Tong-Lin Wu T et al. · 2018In vitroInduction of apoptosis in prostate cancer by ginsenoside Rh2 — in vitroView study →4Reference 4Peng K et al. · 2022In vitroGinsenoside Rh2 inhibits breast cancer cell growth via ERβ-TNFα pathway — in vitro and in vivoView study →7Reference 7Wang J et al. · 2020In vitroGinsenoside Rh2 represses autophagy to promote cervical cancer cell apoptosis during starvation — in vitroView study →}. In hepatocellular-carcinoma cells it upregulates the death receptor DR5 to promote TRAIL-induced apoptosis ^{10Reference 10Liu W et al. · 2022In vitroLiu W, et al. (2022). 20(s)-ginsenoside Rh2 promotes TRAIL-induced apoptosis by upregulating DR5 in human hepatocellular carcinoma cells — in vitro. Medical Oncology. https://pubmed.ncbi.nlm.nih.gov/35568793/View study →}, and activates GSK-3β to drive β-catenin degradation ^{14Reference 14Shi Q et al. · 2016In vitroAnticancer effect of 20(S)-ginsenoside Rh2 on HepG2 liver carcinoma cells: activating GSK-3β and degrading β-catenin — in vitroView study →}.

Autophagy is context-dependent. In cervical-cancer cells under starvation, Rh2 represses protective autophagy to push cells toward apoptosis ^{7Reference 7Wang J et al. · 2020In vitroGinsenoside Rh2 represses autophagy to promote cervical cancer cell apoptosis during starvation — in vitroView study →}; in a separate cervical model it induced apoptosis and protective autophagy by inhibiting AMPK/mTOR ^{8Reference 8Bian S et al. · 2021In vitroBian S, et al. (2021). 20(S)-Ginsenoside Rh2-induced apoptosis and protective autophagy in cervical cancer cells by inhibiting the AMPK/mTOR pathway — in vitro. Bioscience, Biotechnology, and Biochemistry. https://pubmed.ncbi.nlm.nih.gov/34718401/View study →} — a reminder that the autophagy story cuts both ways depending on the model.

Metabolism, epigenetics and metastasis round out the mechanism map. In non-small-cell lung cancer, Rh2 shifted tumour metabolism away from aerobic glycolysis toward oxidative phosphorylation via the HIF-1α/PDK4 axis ^{9Reference 9Liu X et al. · 2024In vitroGinsenoside Rh2 shifts tumor metabolism from aerobic glycolysis to oxidative phosphorylation through regulating the HIF-1α/PDK4 axis in non-small cell lung cancer — in vitro/in vivoView study →}; in leukaemia and hepatoma cells it acts as a histone-deacetylase (HDAC) inhibitor ^{11Reference 11Qiang SQ et al. · 2021In vitroAnticancer effect of Rh2 in HepG2 cells and HepG2 cell-derived xenograft tumors via HDAC inhibition and the MAPK pathway — in vitro and in vivoView study →13Reference 13Liu ZH et al. · 2015In vitroGinsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells — in vitroView study →}; and it suppresses proliferation/invasion pathways such as IL-6/JAK2/STAT3 (triple-negative breast) ^{5Reference 5Ding R et al. · 2024In vitroGinsenoside Rh2 regulates triple-negative breast cancer proliferation and apoptosis via the IL-6/JAK2/STAT3 pathway — in vitroView study →} and a miR-150-3p/SRCIN1/Wnt axis (colon) ^{6Reference 6Li S et al. · 2023In vitroGinsenoside Rh2 suppresses colon cancer growth by targeting the miR-150-3p/SRCIN1/Wnt axis — in vitro/in vivoView study →}. Several of these were confirmed to slow growth of cell-line-derived xenograft tumours in mice ^{11Reference 11Qiang SQ et al. · 2021In vitroAnticancer effect of Rh2 in HepG2 cells and HepG2 cell-derived xenograft tumors via HDAC inhibition and the MAPK pathway — in vitro and in vivoView study →12Reference 12Xia T et al. · 2020In vitroXia T, et al. (2020). 20(S)-Ginsenoside Rh2 displays efficacy against T-cell acute lymphoblastic leukemia through the PI3K/Akt/mTOR signal pathway — in vitro/in vivo. Journal of Ginseng Research. https://pubmed.ncbi.nlm.nih.gov/32913402/View study →}.

Chemo-sensitization is a distinct and arguably more translationally interesting thread: Rh2 both reverses P-glycoprotein-mediated multidrug resistance (as a P-gp inhibitor) ^{16Reference 16Zhang J et al. · 2012In vitroStereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics — in vitro/in vivoView study →} and, in an NSCLC model, enhanced cisplatin sensitivity in vivo and in vitro by targeting Aurora kinase A (AURKA) ^{15Reference 15Chen Y et al. · 2026In vitroGinsenoside Rh2 inhibits non-small-cell lung cancer malignant progression through targeting AURKA and enhancing cisplatin sensitivity — in vitro/in vivoView study →}. As an adjunct that makes tumour cells more responsive to an established drug, this is a different — and, mechanistically, better-anchored — proposition than Rh2 as a stand-alone cure.

The load-bearing caveat sits under everything above: these are isolated-molecule studies in cells and mice, usually with 20(S)-Rh2 delivered at doses/routes chosen to bypass poor oral uptake. None of it establishes efficacy, dose, or safety as a human cancer therapy.

What It's Used For

Beyond oncology, Rh2 has a scattering of anti-inflammatory, immune and metabolic signals — again preclinical. The evidence below is scored across applications; read each row’s basis, because the scores mix a large anticancer literature with much thinner side-lines, and every row is isolated-molecule, non-human.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume, tempered for isolate-vs-plant match and bioavailability. A beta, not a validated metric. Every row rests on isolated Rh2 in cells or animals, so scores are capped. Each application links to its write-up.

01Anticancer (preclinical)Shaky44%Large in-vitro + some rodent xenograft literature across many tumour types; 20(S)-Rh2; no human oncology trial ^{1Reference 1Hu QR et al. · 2023In vitroThe ways for ginsenoside Rh2 to fight against cancer: the molecular evidences in vitro and in vivo — reviewView study →2Reference 2Guan W · 2023ReviewGinsenoside Rh2: A shining and potential natural product in the treatment of human nonmalignant and malignant diseases in the near future — reviewView study →3Reference 3Tong-Lin Wu T et al. · 2018In vitroInduction of apoptosis in prostate cancer by ginsenoside Rh2 — in vitroView study →}

02Chemo-sensitization / MDR reversalShaky30%Isolated Rh2; P-gp inhibition + cisplatin/AURKA model; mechanism-level, no clinical endpoint ^{15Reference 15Chen Y et al. · 2026In vitroGinsenoside Rh2 inhibits non-small-cell lung cancer malignant progression through targeting AURKA and enhancing cisplatin sensitivity — in vitro/in vivoView study →16Reference 16Zhang J et al. · 2012In vitroStereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics — in vitro/in vivoView study →}

03Anti-inflammatory / immuneShaky22%Rodent/cell models (dermatitis, arthritis, colitis, neuropathic pain); isolated Rh2 ^{25Reference 25Ko E et al. · 2019AnimalGinsenoside Rh2 ameliorates atopic dermatitis in NC/Nga mice by suppressing NF-κB-mediated thymic stromal lymphopoietin expression and T helper type 2 differentiation — in vivoView study →26Reference 26Fu YY et al. · 2022AnimalGinsenoside Rh2 ameliorates neuropathic pain by inhibition of the miRNA21-TLR8-mitogen-activated protein kinase axis — in vivoView study →27Reference 27Zhou Z et al. · 2025AnimalGinsenoside Rh2-pretreated mesenchymal stem cell exosomes ameliorate collagen-induced arthritis via N6-methyladenosine methylation — in vivoView study →}

04Metabolic / otherShaky12%Scattered mechanistic signals; isolated Rh2; thin, indirect

Mechanisms

Pharmacokinetics

Poor oral bioavailability is the load-bearing fact. As a lipophilic monoglucoside saponin, Rh2 is limited on the way into the body by two documented barriers: active efflux by P-glycoprotein and first-pass metabolism by CYP3A4, both established in absorption/efflux studies and Caco-2 monolayers ^{18Reference 18Yang Z et al. · 2011In vitroEnhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms — in vitro/in vivoView study →21Reference 21Xie HT et al. · 2005In vitroUptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco-2 cells — in vitroView study →}. Co-administering the P-gp/CYP inhibitor piperine raised Rh2’s oral bioavailability and immune response, confirming those gatekeepers ^{20Reference 20Jin ZH et al. · 2018AnimalEnhancement of oral bioavailability and immune response of ginsenoside Rh2 by co-administration with piperine — in vivoView study →}. In the gut and gut wall, Rh2 is deglycosylated to its aglycone protopanaxadiol (PPD), so oral exposure is partly exposure to PPD, and the two share stereoselective P-gp behaviour ^{16Reference 16Zhang J et al. · 2012In vitroStereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics — in vitro/in vivoView study →21Reference 21Xie HT et al. · 2005In vitroUptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco-2 cells — in vitroView study →}. Pharmacokinetics are epimer-dependent — 20(S) and 20(R) differ in P-gp handling ^{16Reference 16Zhang J et al. · 2012In vitroStereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics — in vitro/in vivoView study →}.

Uniquely among the ginsenosides here, Rh2 has a human pharmacokinetic dataset: a healthy-subject study of a ginsenoside-Rh2 dripping-pill formulation (7.8–31.2 mg) found it was absorbed at medium speed with a median Cmax at ~3 h, showed dose-proportional AUC/Cmax, and reached steady state without accumulation over five days of twice-daily dosing ^{19Reference 19Wang Z et al. · 2021Pharmacokinetics of ginsenoside Rh2, the major anticancer ingredient of ginsenoside H dripping pills, in healthy subjects — human pharmacokinetic studyView study →}. That is a formulation-PK study in healthy volunteers, not an efficacy trial — it tells us Rh2 can be measured in human plasma, not that it does anything therapeutic there.

Clinical Trials

There are no efficacy trials of isolated Rh2 in cancer or any other disease. The only human data is the healthy-subject pharmacokinetic study of a dripping-pill formulation ^{19Reference 19Wang Z et al. · 2021Pharmacokinetics of ginsenoside Rh2, the major anticancer ingredient of ginsenoside H dripping pills, in healthy subjects — human pharmacokinetic studyView study →}; all disease-level evidence is preclinical, and all whole-ginseng human data belong to standardized extracts, not isolated Rh2.

Last checked: July 2026.

Isolate vs. Plant Studies

Rh2 sits at an awkward point on the isolate-vs-plant axis. The evidence is almost entirely isolated-molecule — pure 20(S)-Rh2 in cell and rodent models — which is a strength for attributing effects to the molecule, but a weakness for translating them, because you cannot get much Rh2 from eating ginseng. Raw white ginseng carries only traces; even red/steamed/fermented ginseng, which is enriched, delivers Rh2 as one minor saponin among dozens, and ginseng’s actual human evidence is for whole standardized extract, not Rh2 ^{23Reference 23Bae EA et al. · 2004AnimalProtective effect of fermented red ginseng on transient focal ischemic rats (fermentation yields compound K > Rg3 ≥ Rh2) — in vivoView study →24Reference 24Song H et al. · 2020Simultaneous quantification of six nonpolar ginsenosides in white ginseng by reversed-phase HPLC — analyticalView study →}. Meanwhile the marketed “Rh2 supplements” are concentrated isolate/semisynthetic preparations, decoupled from the plant — so the relevant caveat is not “isolate results won’t transfer to the plant” but “isolate results in a dish won’t transfer to a poorly-absorbed oral capsule in a person” ^{18Reference 18Yang Z et al. · 2011In vitroEnhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms — in vitro/in vivoView study →19Reference 19Wang Z et al. · 2021Pharmacokinetics of ginsenoside Rh2, the major anticancer ingredient of ginsenoside H dripping pills, in healthy subjects — human pharmacokinetic studyView study →}. Which epimer a given preparation contains further complicates read-across ^{16Reference 16Zhang J et al. · 2012In vitroStereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics — in vitro/in vivoView study →17Reference 17Yang J et al. · 2016In vitroSemisynthesis and bioactive evaluation of oxidized products from 20(S)-ginsenoside Rg3, Rh2, protopanaxadiol (PPD) and their 20(R)-epimers as cytotoxic agents — in vitroView study →}.

Prevalence in Nature

Rh2 is a minor ginsenoside — genuinely scarce in the raw plant. It is present at trace levels in raw white Panax ginseng and is enriched by processing: steaming to make red (and, with repeated cycles, black) ginseng cleaves sugars from the abundant PPD majors (Rb1/Rc/Rd) to yield the less-polar minors including Rh2, Rg3, Rk1 and Rg5 ^{24Reference 24Song H et al. · 2020Simultaneous quantification of six nonpolar ginsenosides in white ginseng by reversed-phase HPLC — analyticalView study →}. Fermentation does the same biologically, producing compound K, Rg3 and Rh2 as principal metabolites ^{23Reference 23Bae EA et al. · 2004AnimalProtective effect of fermented red ginseng on transient focal ischemic rats (fermentation yields compound K > Rg3 ≥ Rh2) — in vivoView study →}. It also occurs in American ginseng (P. quinquefolius) and notoginseng (P. notoginseng), and in their processed forms. Because it is a downstream deglycosylation product rather than a stored primary metabolite, its concentration depends heavily on processing method and degree rather than on the fresh root — quantitative figures for a “typical” content are not well characterized, and commercial Rh2 is usually concentrated or semisynthesized rather than extracted at natural abundance.

Discovery & Synthesis

Rh2 was characterized among the minor, less-polar saponins of red (steamed) ginseng in the early 1980s, as Japanese and Korean phytochemists worked out why processed ginseng differed chemically from the raw root. It became a research focus soon after, when minor ginsenosides of the protopanaxadiol series were among the first ginseng saponins reported to inhibit tumour-cell growth and induce differentiation (mid-1980s) — the origin of Rh2’s enduring anticancer reputation. A clean first total synthesis is not well documented; the molecule is defined by its relationship to the major saponins rather than by a landmark synthesis.

Manufacture today is overwhelmingly by conversion rather than extraction: because natural abundance is so low, commercial Rh2 is produced by deglycosylating the abundant major ginsenosides — via controlled steaming/acid hydrolysis, enzymatic (β-glucosidase) processing, or microbial fermentation — to strip Rb1/Rc/Rd down toward the monoglucoside, then purifying (and where needed resolving) the 20(S) epimer ^{23Reference 23Bae EA et al. · 2004AnimalProtective effect of fermented red ginseng on transient focal ischemic rats (fermentation yields compound K > Rg3 ≥ Rh2) — in vivoView study →24Reference 24Song H et al. · 2020Simultaneous quantification of six nonpolar ginsenosides in white ginseng by reversed-phase HPLC — analyticalView study →}. This makes marketed Rh2 a semi-manufactured molecule, and its epimeric purity a manufacturing variable.

Patents: not yet researched.

Toxicity & Safety

Rh2 carries a low flag at the exposures studied. Its defining pharmacology is preclinical cytotoxicity that is relatively selective for tumour cells, and the one human dataset — a healthy-subject PK study up to 31.2 mg twice daily for five days — reported dose-proportional exposure reaching steady state without accumulation, consistent with good tolerability at those doses ^{19Reference 19Wang Z et al. · 2021Pharmacokinetics of ginsenoside Rh2, the major anticancer ingredient of ginsenoside H dripping pills, in healthy subjects — human pharmacokinetic studyView study →}. The cautions below are largely theoretical or mechanism-derived, not established human harms.

Safety at a Glance

✅ Low / no toxicity

• Well-tolerated in the one human PK study. Dose-proportional, steady-state without accumulation over five days at up to ~31 mg twice daily (healthy subjects) ^{19Reference 19Wang Z et al. · 2021Pharmacokinetics of ginsenoside Rh2, the major anticancer ingredient of ginsenoside H dripping pills, in healthy subjects — human pharmacokinetic studyView study →}.
• Drug-interaction potential via P-gp and CYP3A4. Rh2 inhibits P-glycoprotein (stereoselectively) and is a CYP3A4 substrate/inhibitor, so it can alter the absorption of co-administered P-gp/CYP3A4 drugs — the same property behind its MDR-reversal and its piperine-boosted uptake ^{16Reference 16Zhang J et al. · 2012In vitroStereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics — in vitro/in vivoView study →18Reference 18Yang Z et al. · 2011In vitroEnhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms — in vitro/in vivoView study →20Reference 20Jin ZH et al. · 2018AnimalEnhancement of oral bioavailability and immune response of ginsenoside Rh2 by co-administration with piperine — in vivoView study →}.
• A cytotoxic, pro-apoptotic molecule by design. Its studied activity is killing dividing cells; long-term safety of concentrated isolate supplementation in people is uncharacterized, and epimeric purity (20(S) vs 20(R)) is rarely disclosed ^{17Reference 17Yang J et al. · 2016In vitroSemisynthesis and bioactive evaluation of oxidized products from 20(S)-ginsenoside Rg3, Rh2, protopanaxadiol (PPD) and their 20(R)-epimers as cytotoxic agents — in vitroView study →}.
• Marketing outruns evidence. “Rh2 for cancer” claims rest on preclinical data only — there is no human efficacy trial; anyone with cancer should treat Rh2 as experimental, not a therapy, and discuss any use alongside oncology drugs given the interaction potential.

No dedicated reproductive-toxicity dataset exists for isolated Rh2; pregnancy and lactation decisions belong to the herb or product page where intake is decided, not to this molecule page. No comprehensive isolate genotoxicity or repeat-dose package is characterized here beyond the anticancer/PK literature above.

Dosage

There is no established human dose of isolated ginsenoside Rh2. It is a research compound and a marketed supplement ingredient, not a standardized medicine. The only human figures come from a pharmacokinetic study, which dosed a Rh2 dripping-pill formulation at 7.8, 15.6 and 31.2 mg in healthy volunteers to characterize absorption — not to establish an effective dose for any condition ^{19Reference 19Wang Z et al. · 2021Pharmacokinetics of ginsenoside Rh2, the major anticancer ingredient of ginsenoside H dripping pills, in healthy subjects — human pharmacokinetic studyView study →}. Preclinical anticancer work used isolated 20(S)-Rh2 in cells and rodents, at doses/routes chosen to overcome poor oral uptake, none of which translate to a human oral dose ^{1Reference 1Hu QR et al. · 2023In vitroThe ways for ginsenoside Rh2 to fight against cancer: the molecular evidences in vitro and in vivo — reviewView study →2Reference 2Guan W · 2023ReviewGinsenoside Rh2: A shining and potential natural product in the treatment of human nonmalignant and malignant diseases in the near future — reviewView study →}. Because oral Rh2 is poorly absorbed and partly converted to protopanaxadiol, a milligram figure on a label does not map cleanly onto delivered exposure ^{18Reference 18Yang Z et al. · 2011In vitroEnhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms — in vitro/in vivoView study →21Reference 21Xie HT et al. · 2005In vitroUptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco-2 cells — in vitroView study →}. These are doses studied in research and are not a personal recommendation.

References

1. Hu QR, Pan Y, Wu HC, et al. (2023). The ways for ginsenoside Rh2 to fight against cancer: the molecular evidences in vitro and in vivo — review. Journal of Ginseng Research. https://pubmed.ncbi.nlm.nih.gov/36926617/
2. Guan W, Qi W (2023). Ginsenoside Rh2: A shining and potential natural product in the treatment of human nonmalignant and malignant diseases in the near future — review. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/37406390/
3. Tong-Lin Wu T, Tong YC, Chen IH, et al. (2018). Induction of apoptosis in prostate cancer by ginsenoside Rh2 — in vitro. Oncotarget. https://pubmed.ncbi.nlm.nih.gov/29541400/
4. Peng K, Luo T, Li J, et al. (2022). Ginsenoside Rh2 inhibits breast cancer cell growth via ERβ-TNFα pathway — in vitro and in vivo. Acta Biochimica et Biophysica Sinica. https://pubmed.ncbi.nlm.nih.gov/35593465/
5. Ding R, et al. (2024). Ginsenoside Rh2 regulates triple-negative breast cancer proliferation and apoptosis via the IL-6/JAK2/STAT3 pathway — in vitro. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/39845783/
6. Li S, et al. (2023). Ginsenoside Rh2 suppresses colon cancer growth by targeting the miR-150-3p/SRCIN1/Wnt axis — in vitro/in vivo. Acta Biochimica et Biophysica Sinica. https://pubmed.ncbi.nlm.nih.gov/36916297/
7. Wang J, et al. (2020). Ginsenoside Rh2 represses autophagy to promote cervical cancer cell apoptosis during starvation — in vitro. Chinese Medicine. https://pubmed.ncbi.nlm.nih.gov/33292331/
8. Bian S, et al. (2021). 20(S)-Ginsenoside Rh2-induced apoptosis and protective autophagy in cervical cancer cells by inhibiting the AMPK/mTOR pathway — in vitro. Bioscience, Biotechnology, and Biochemistry. https://pubmed.ncbi.nlm.nih.gov/34718401/
9. Liu X, et al. (2024). Ginsenoside Rh2 shifts tumor metabolism from aerobic glycolysis to oxidative phosphorylation through regulating the HIF-1α/PDK4 axis in non-small cell lung cancer — in vitro/in vivo. Molecular Medicine. https://pubmed.ncbi.nlm.nih.gov/38671369/
10. Liu W, et al. (2022). 20(s)-ginsenoside Rh2 promotes TRAIL-induced apoptosis by upregulating DR5 in human hepatocellular carcinoma cells — in vitro. Medical Oncology. https://pubmed.ncbi.nlm.nih.gov/35568793/
11. Qiang SQ, et al. (2021). Anticancer effect of Rh2 in HepG2 cells and HepG2 cell-derived xenograft tumors via HDAC inhibition and the MAPK pathway — in vitro and in vivo. Asian Pacific Journal of Cancer Prevention. https://pubmed.ncbi.nlm.nih.gov/34452568/
12. Xia T, et al. (2020). 20(S)-Ginsenoside Rh2 displays efficacy against T-cell acute lymphoblastic leukemia through the PI3K/Akt/mTOR signal pathway — in vitro/in vivo. Journal of Ginseng Research. https://pubmed.ncbi.nlm.nih.gov/32913402/
13. Liu ZH, et al. (2015). Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells — in vitro. Chemico-Biological Interactions. https://pubmed.ncbi.nlm.nih.gov/26482938/
14. Shi Q, et al. (2016). Anticancer effect of 20(S)-ginsenoside Rh2 on HepG2 liver carcinoma cells: activating GSK-3β and degrading β-catenin — in vitro. Oncology Reports. https://pubmed.ncbi.nlm.nih.gov/27573179/
15. Chen Y, Zhu W, Xiang P, et al. (2026). Ginsenoside Rh2 inhibits non-small-cell lung cancer malignant progression through targeting AURKA and enhancing cisplatin sensitivity — in vitro/in vivo. Naunyn-Schmiedeberg’s Archives of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/42142138/
16. Zhang J, Zhou F, Niu F, et al. (2012). Stereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics — in vitro/in vivo. PLoS One. https://pubmed.ncbi.nlm.nih.gov/22530069/
17. Yang J, Li X, Sun T, et al. (2016). Semisynthesis and bioactive evaluation of oxidized products from 20(S)-ginsenoside Rg3, Rh2, protopanaxadiol (PPD) and their 20(R)-epimers as cytotoxic agents — in vitro. Steroids. https://pubmed.ncbi.nlm.nih.gov/26703442/
18. Yang Z, et al. (2011). Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms — in vitro/in vivo. Drug Metabolism and Disposition. https://pubmed.ncbi.nlm.nih.gov/21757611/
19. Wang Z, Liu R, Chen L, et al. (2021). Pharmacokinetics of ginsenoside Rh2, the major anticancer ingredient of ginsenoside H dripping pills, in healthy subjects — human pharmacokinetic study. Clinical Pharmacology in Drug Development. https://pubmed.ncbi.nlm.nih.gov/33021081/
20. Jin ZH, et al. (2018). Enhancement of oral bioavailability and immune response of ginsenoside Rh2 by co-administration with piperine — in vivo. Chinese Journal of Natural Medicines. https://pubmed.ncbi.nlm.nih.gov/29455730/
21. Xie HT, et al. (2005). Uptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco-2 cells — in vitro. Biological & Pharmaceutical Bulletin. https://pubmed.ncbi.nlm.nih.gov/15684507/
22. Gu Y, et al. (2009). Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs — in vivo. Food and Chemical Toxicology. https://pubmed.ncbi.nlm.nih.gov/19524010/
23. Bae EA, Hyun YJ, Choo MK, et al. (2004). Protective effect of fermented red ginseng on transient focal ischemic rats (fermentation yields compound K > Rg3 ≥ Rh2) — in vivo. Archives of Pharmacal Research. https://pubmed.ncbi.nlm.nih.gov/15595417/
24. Song H, Song KW, Hong SP (2020). Simultaneous quantification of six nonpolar ginsenosides in white ginseng by reversed-phase HPLC — analytical. Journal of Ginseng Research. https://pubmed.ncbi.nlm.nih.gov/32617036/
25. Ko E, et al. (2019). Ginsenoside Rh2 ameliorates atopic dermatitis in NC/Nga mice by suppressing NF-κB-mediated thymic stromal lymphopoietin expression and T helper type 2 differentiation — in vivo. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/31817146/
26. Fu YY, et al. (2022). Ginsenoside Rh2 ameliorates neuropathic pain by inhibition of the miRNA21-TLR8-mitogen-activated protein kinase axis — in vivo. Molecular Pain. https://pubmed.ncbi.nlm.nih.gov/36039405/
27. Zhou Z, et al. (2025). Ginsenoside Rh2-pretreated mesenchymal stem cell exosomes ameliorate collagen-induced arthritis via N6-methyladenosine methylation — in vivo. Biomaterials Research. https://pubmed.ncbi.nlm.nih.gov/40502627/
28. Xia T, et al. (2020). New insight into 20(S)-ginsenoside Rh2 against T-cell acute lymphoblastic leukemia associated with the gut microbiota and the immune system — in vivo. European Journal of Medicinal Chemistry. https://pubmed.ncbi.nlm.nih.gov/32682197/

View all 28 references▾